108 related articles for article (PubMed ID: 2959409)
1. Visual and cutaneous toxicity which occurs during N-(4-hydroxyphenyl) retinamide therapy for psoriasis.
Kingston TP; Lowe NJ; Winston J; Heckenlively J
Clin Exp Dermatol; 1986 Nov; 11(6):624-7. PubMed ID: 2959409
[No Abstract] [Full Text] [Related]
2. Ocular toxic effects of fenretinide.
Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
J Natl Cancer Inst; 1990 Jun; 82(12):1063. PubMed ID: 2140863
[No Abstract] [Full Text] [Related]
3. Tolerability of the synthetic retinoid Fenretinide (HPR).
Costa A; Malone W; Perloff M; Buranelli F; Campa T; Dossena G; Magni A; Pizzichetta M; Andreoli C; Del Vecchio M
Eur J Cancer Clin Oncol; 1989 May; 25(5):805-8. PubMed ID: 2525470
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
[TBL] [Abstract][Full Text] [Related]
5. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients.
Rotmensz N; De Palo G; Formelli F; Costa A; Marubini E; Campa T; Crippa A; Danesini GM; Delle Grottaglie M; Di Mauro MG
Eur J Cancer; 1991; 27(9):1127-31. PubMed ID: 1835622
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of fenretinide [N-(4-hydroxyphenyl) retinamide] in myelodysplasia: possible retinoid-induced disease acceleration.
Garewal HS; List A; Meyskens F; Buzaid A; Greenberg B; Katakkar S
Leuk Res; 1989; 13(4):339-43. PubMed ID: 2523991
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma.
Modiano MR; Dalton WS; Lippman SM; Joffe L; Booth AR; Meyskens FL
Invest New Drugs; 1990 Aug; 8(3):317-9. PubMed ID: 2148744
[TBL] [Abstract][Full Text] [Related]
8. Putative metabolites derived from dietary combinations of calcium glucarate and N-(4-hydroxyphenyl)retinamide act synergistically to inhibit the induction of rat mammary tumors by 7,12-dimethylbenz[a]anthracene.
Abou-Issa HM; Duruibe VA; Minton JP; Larroya S; Dwivedi C; Webb TE
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4181-4. PubMed ID: 2967969
[TBL] [Abstract][Full Text] [Related]
9. Subacute toxicity of all-trans- and 13-cis-isomers of N-ethyl retinamide, N-2-hydroxyethyl retinamide, and N-4-hydroxyphenyl retinamide.
Sani BP; Meeks RG
Toxicol Appl Pharmacol; 1983 Sep; 70(2):228-35. PubMed ID: 6226123
[TBL] [Abstract][Full Text] [Related]
10. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
[TBL] [Abstract][Full Text] [Related]
11. Analysis of N-(4-hydroxyphenyl)retinamide polymorphic forms by X-ray powder diffraction.
Chrzanowski FA; Fegely BJ; Sisco WR; Newton MP
J Pharm Sci; 1984 Oct; 73(10):1448-50. PubMed ID: 6239027
[TBL] [Abstract][Full Text] [Related]
12. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide.
Pollard M; Luckert PH; Sporn MB
Cancer Res; 1991 Jul; 51(13):3610-1. PubMed ID: 1829024
[TBL] [Abstract][Full Text] [Related]
13. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
Conley B; O'Shaughnessy J; Prindiville S; Lawrence J; Chow C; Jones E; Merino MJ; Kaiser-Kupfer MI; Caruso RC; Podgor M; Goldspiel B; Venzon D; Danforth D; Wu S; Noone M; Goldstein J; Cowan KH; Zujewski J
J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
[TBL] [Abstract][Full Text] [Related]
14. Simple high-performance liquid chromatographic method for the separation of retinoids including N-(4-hydroxyphenyl)-all-trans-retinamide.
Hultin TA; Mehta RG; Moon RC
J Chromatogr; 1985 May; 341(1):187-92. PubMed ID: 3160718
[No Abstract] [Full Text] [Related]
15. Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues.
Vratilova J; Frgala T; Maurer BJ; Patrick Reynolds C
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Sep; 808(2):125-30. PubMed ID: 15261805
[TBL] [Abstract][Full Text] [Related]
16. [Side effects of oral retinoid Ro 10-9359 on the unaffected skin of psoriatic patients: retinoid dermatitis].
Rüst O; Tufli T
Schweiz Med Wochenschr; 1979 Dec; 109(48):1921-5. PubMed ID: 161414
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats.
Swanson BN; Zaharevitz DW; Sporn MB
Drug Metab Dispos; 1980; 8(3):168-72. PubMed ID: 6104581
[TBL] [Abstract][Full Text] [Related]
18. In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences.
Berni R; Formelli F
FEBS Lett; 1992 Aug; 308(1):43-5. PubMed ID: 1386578
[TBL] [Abstract][Full Text] [Related]
19. Effects of pretreatment with the retinoid N-(4-hydroxyphenyl)-all-trans-retinamide and phenobarbital on the disposition and metabolism of N-(4-hydroxyphenyl)-all-trans-retinamide in mice.
Hultin TA; McCormick DL; May CM; Moon RC
Drug Metab Dispos; 1988; 16(6):783-8. PubMed ID: 2907453
[TBL] [Abstract][Full Text] [Related]
20. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide.
Formelli F; Barua AB; Olson JA
FASEB J; 1996 Jul; 10(9):1014-24. PubMed ID: 8801162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
